The electrophoresis-mobility test is an in-vitro method for demonstrating specific sensitized lymphocytes. After incubation with the encephalitogenic factor, lymphocytes from patients with malignant disease liberate a factor which causes a decrease in migration velocity of indicator cells (tanned and sulphosalicyl acid-stabilised sheep erythrocytes = ETS) in an electrical field. 84 patients with pulmonary disease and 20 control persons were examined. An inhibition of ETS migration was found only in patients with malignant pulmonary disease, while in the control subjects and those with inflammatory or degenerative pulmonary disease or benign pulmonary tumour ETS migration was accelerated. The difference between the two groups is statistically significant so that it provides a reliable differentiation between benign and malignant disease. False-negative results, however, occur under radiotherapy and chemotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0028-1104903DOI Listing

Publication Analysis

Top Keywords

malignant disease
12
pulmonary disease
12
electrophoresis-mobility test
8
patients malignant
8
disease control
8
ets migration
8
disease
6
[immunodiagnosis malignant
4
disease electrophoresis-mobility
4
test diagnosis
4

Similar Publications

Corneal Perforation Associated with Pembrolizumab - A Case Report with Literature Review.

Ocul Immunol Inflamm

January 2025

Universiti Malaya Eye Research Centre (UMERC), Department of Ophthalmology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.

Purpose: To shed light on one of the ocular adverse effects related to pembrolizumab.

Method: Case report and literature review.

Result: A 53-year-old gentleman with underlying Stage III B renal cell carcinoma with lung metastasis and gout presented in June 2021 with bilateral red eyes following Coronavirus disease (COVID-19) vaccination.

View Article and Find Full Text PDF

Purpose: Prior noncontemporary studies showed that oral cyclophosphamide is an active treatment of metastatic castration-resistant prostate cancer (mCRPC). However, cyclophosphamide is currently underutilized in routine clinical practice given the lack of survival benefit and the emergence of more effective treatments.

Methods: We retrospectively reviewed our institutional database to identify patients with mCRPC treated with cyclophosphamide.

View Article and Find Full Text PDF

Purpose: Pancreatic cancer is one of the deadliest cancers in the world. In Armenia, it is 12th by incidence. The aim of this study is to evaluate treatment and outcomes of pancreatic cancer in Armenia during the past 12 years.

View Article and Find Full Text PDF

The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in bladder cancer. The National Comprehensive Cancer Network recommends that all patients with stage IVA and stage IVB urothelial carcinoma have molecular analysis that integrates at least testing to help facilitate the selection of future therapeutic options. Sequencing of tumor-derived tissue is the mainstay to obtain this genomic testing, but as in other cancers, there has been extensive research into the integration of liquid biopsies in longitudinal management.

View Article and Find Full Text PDF

Understanding how epithelial cells in the female reproductive tract (FRT) differentiate is crucial for reproductive health, yet the underlying mechanisms remain poorly defined. At birth, FRT epithelium is highly malleable, allowing differentiation into various epithelial types, but the regulatory pathways guiding these early cell fate decisions are unclear. Here, we use neonatal mouse endometrial organoids and assembloid coculture models to investigate how innate cellular plasticity and external mesenchymal signals influence epithelial differentiation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!